Literature DB >> 10443652

Low dose hexarelin and growth hormone (GH)-releasing hormone as a diagnostic tool for the diagnosis of GH deficiency in adults: comparison with insulin-induced hypoglycemia test.

M Gasperi1, G Aimaretti, G Scarcello, G Corneli, C Cosci, E Arvat, E Martino, E Ghigo.   

Abstract

GH deficiency (GHD) in adults must be shown by provocative testing of GH secretion. Insulin-induced hypoglycemia (ITT) is the test of choice, and severe GHD, treated with recombinant human GH replacement, is defined by a GH peak response to ITT of less than 3 microg/L. GHRH plus arginine (ARG) is a more provocative test and is as sensitive as ITT provided that appropriate cut-off limits are assumed. GH secretagogues are a family of peptidyl and nonpeptidyl GH-releasing molecules that strongly stimulate GH secretion and, even at low doses, truly synergize with GHRH. Our aim was to verify the diagnostic reliability of the hexarelin (HEX; 0.25 microg/kg, iv) and GHRH (1 microg/kg, iv) test for the diagnosis of adult GHD. To this goal, in the present study we 1) defined the normal ranges of the GH response to GHRH+HEX in a group of normal young adult volunteers (NS; n = 25; 18 men and 7 women; age, 28.5+/-0.6 yr) and in 11 of them verified its reproducibility in a second session, and 2) compared the GH response to GHRH+HEXwith that to ITT in a group of normal subjects (n = 33; 12 men and 21 women; age, 34.1+/-1.5 yr) and hypopituitaric adults with GHD (n = 19; 10 men and 9 women; age, 39.9+/-2.2 yr; GH peak <5 microg/L after ITT). The GH response to GHRH+ARG was also evaluated in all GHD and in 77 normal subjects (40 men and 37 women; age, 28.1+/-0.6 yr). The mean GH peak after GHRH+HEX in NS was 83.6+/-4.5 microg/L; the third and first percentile limits of the normal GH response were 55.5 and 51.2 microg/L, respectively). The GH response to GHRH+HEX in NS showed good intraindividual reproducibility. In GHD the mean GH peak after GHRH+HEX (2.6+/-0.7 microg/L) was similar to that after GHRH+ARG (3.6+/-1.0 microg/L), and both were higher (P < 0.001) than that after ITT (0.6+/-0.1 microg/L); the GH responses to GHRH+HEX were positively associated with those to ITT and GHRH+ARG. Analyzing individual GH responses, 100% had severe GHD after ITT (GH peak, <3 microg/L). After GHRH+HEX all GHD had GH peaks below the third percentile limit of normality appropriate for this test (i.e. 55.5 microg/L). Thirteen of 19 (68.4%) GHD subjects had GH peaks below 3 microg/L after GHRH+HEX but all 19 (100%) had GH peaks below the first percentile limit of normality (i.e. 51.2 microg/L). The GH responses to GHRH+HEX were highly concordant with those after GHRH+ARG. In conclusion, the present results define normal limits of the GH response to stimulation with low dose HEX+GHRH in normal adults and show that this test is as sensitive as ITT for the diagnosis of adult GHD provided that appropriate cut-off limits are considered.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10443652     DOI: 10.1210/jcem.84.8.5904

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  11 in total

Review 1.  Intranasally and orally active GH secretagogues are useful clinical tools: so why are they not on the market?

Authors:  Z Laron
Journal:  J Endocrinol Invest       Date:  2003-01       Impact factor: 4.256

Review 2.  Diagnosis of adult growth hormone deficiency: still a matter of debate.

Authors:  F Camanni
Journal:  J Endocrinol Invest       Date:  2006-02       Impact factor: 4.256

Review 3.  Implications of ghrelin and hexarelin in diabetes and diabetes-associated heart diseases.

Authors:  Rasha Mofeed Habeeb Mosa; Zhen Zhang; Renfu Shao; Chao Deng; Jiezhong Chen; Chen Chen
Journal:  Endocrine       Date:  2015-02-04       Impact factor: 3.633

4.  Hexarelin: a multi-receptor peptide.

Authors:  R Deghenghi
Journal:  J Endocrinol Invest       Date:  2008-07       Impact factor: 4.256

5.  Impairment of GH secretion in adults with primary empty sella.

Authors:  M Gasperi; G Aimaretti; E Cecconi; A Colao; C Di Somma; S Cannavò; C Baffoni; M Cosottini; L Curtò; F Trimarchi; G Lombardi; L Grasso; E Ghigo; E Martino
Journal:  J Endocrinol Invest       Date:  2002-04       Impact factor: 4.256

Review 6.  Growth hormone-releasing hormone combined with arginine or growth hormone secretagogues for the diagnosis of growth hormone deficiency in adults.

Authors:  E Ghigo; G Aimaretti; E Arvat; F Camanni
Journal:  Endocrine       Date:  2001-06       Impact factor: 3.633

Review 7.  Aetiology, diagnosis, and management of hypopituitarism in adult life.

Authors:  V K B Prabhakar; S M Shalet
Journal:  Postgrad Med J       Date:  2006-04       Impact factor: 2.401

8.  Primary hyperparathyroidism is associated with an impaired secretion of growth hormone but not of the other anterior pituitary hormones.

Authors:  E Cecconi; M Gasperi; L Grasso; M Genovesi; G Aimaretti; F Broglio; L Bartalena; C Marcocci; E Martino
Journal:  J Endocrinol Invest       Date:  2002-03       Impact factor: 4.256

Review 9.  Diagnosis of adult GH deficiency.

Authors:  V Gasco; G Corneli; S Rovere; C Croce; G Beccuti; A Mainolfi; S Grottoli; G Aimaretti; E Ghigo
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

Review 10.  Growth hormone levels in the diagnosis of growth hormone deficiency in adulthood.

Authors:  Ginevra Corneli; Valentina Gasco; Flavia Prodam; Silvia Grottoli; Gianluca Aimaretti; Ezio Ghigo
Journal:  Pituitary       Date:  2007       Impact factor: 3.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.